Request a representative visit or G7 15 Day or G7 samples
CSS Do not remove
Dexcom G7 15 Day: A win for adult patients with diabetes, regardless of insulin use*,1
Dexcom G7 15 Day: It’s even a win for patients with type 2 diabetes who do not use insulin2
Unlock better glucose control with CGM1
CGM is shown to help patients with type 2 diabetes not on insulin lower A1C1
A1C trends with CGM
Clinically significant A1C decreases were also observed in patients who used basal or prandial insulin.
Study design: Real-world study of 74,679 type 2 diabetes adults, including 1533 non-insulin users. A1C values analyzed pre-index, 3, 6, and 12 months post-index, represented as mean ±SEM. Significant improvements in A1C were observed at 3 months and sustained throughout the study period (P<.0001). The study also included arms with basal insulin treatment (n=1375) and prandial insulin therapy (n=3122).1
Delivers immediate and sustained TIR3
All type 2 diabetes patients not on insulin who used Dexcom G7 15 Day CGM saw fast, sustained increase in time in range.
Study design: prospective study comparing adult CGM-naive users with T2D not yet on intensive insulin (N=91) with matched controls to determine the effect of CGM on TIR. Patients also had a baseline A1C >7.5.3
G7 15 Day can help you redefine their diabetes journey
Enhanced ease of use and adherence with 15.5-day wear time4
Further lower A1C when paired with a GLP-1 agonist†,5
Associated with reduced cardiovascular risk in as little as 3 months‡,§,2
Why CGM for adults with type 2 diabetes not on insulin?
ADA guidelines recommend CGM as an option for adult patients with type 2 diabetes whether they use6:
- Insulin
- Non-insulin injectable glucose-lowering medications
- Oral glucose-lowering medications
ONLY 
of patients with TYPE 2 DIABETES have adopted CGM7
Blood glucose monitoring (BGM) doesn’t reveal the full story
CGM provides the complete 24-hour picture to help your patients stay in range for longer.8,9
Illustrative model of a 24‑hour blood glucose profile; not derived from an actual patient dataset.
Coverage & Affordability
Extensive coverage through a broad range of commercial and Medicare plans§,9,10
Ready to Prescribe
Patient Profiles
See how Dexcom G7 15 Day works in patient types
A1C=hemoglobin A1C; ADA=American Diabetes Association; ASCVD=atherosclerotic cardiovascular disease; BGM=blood glucose monitoring; CGM=continuous glucose monitoring; CPT=Current Procedural Terminology; DME=durable medical equipment; GLP-1=glucagon-like peptide-1.
*In a retrospective study, diabetes-related hospitalizations reduced 12 months after CGM use: Non-insulin (-31%) Basal insulin (-48%) Prandial insulin (-53%).1 †Retrospective analysis using Optum’s de-identified Clinformatics® database comprised of US administrative claims and linked laboratory data was conducted between 7/1/2018 and 3/31/2023. ‡Results obtained from previous Dexcom device(s). §Cardiovascular risk refers to 10-year ASCVD risk. Visit tools.acc.org/ascvd-risk-estimator-plus to access the American College of Cardiology ASCVD Risk Estimator Plus. ||Based on a person testing blood glucose 5x a day vs. 288 readings using Dexcom CGM. ¶55% of participants surveyed wore Dexcom CGM. #Individual prices may vary depending on insurance coverage. Under Medicare's DME fee schedule, reimbursement and coinsurance for CGMs using CPT codes A4239 and E2103 are the same, regardless of CGM brand.
1 Garg SK, et al. Diabetes Obes Metab. 2024;26(11):5202-5210. 2 Reed J, et al. Diabetes Obes Metab. 2024;26(7):2881-2889. 3 Shields S, et al. Sci Rep. 2024;14(1):31990. 4 Garg SK, et al. Diabetes Technol Ther. 2025;27(6):413-502. 5 Nemlekar P, et al. Am J Manage Care. 2025;31(4):183-188. 6 Diabetes Technology: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S146-S166. 7 Mayberry LS, et al. J Gen Intern Med. 2023;38(11):2546-2552. 8 Dexcom G7 15 Day User Guide. 9 Lind N, et al. Diabetes Care. 2024;47(5):881-889. 10 Dexcom G7 User Guide. 11 Ehrhardt N, et al. Clin Diabetes. 2020;38(2):126-131. 12 Cowart K, et al. Expert Rev Med Devices. 2021;18(11):1049-1055.